×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
HCM – hutchmed (china) limited - american depositary shares (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
HCM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/21
11:08 pm
hcm
HUTCHMED (China) Limited (NASDAQ: HCM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
HUTCHMED (China) Limited (NASDAQ: HCM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
3/21
05:55 pm
hcm
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma [Yahoo! Finance]
Low
Report
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma [Yahoo! Finance]
3/21
06:00 am
hcm
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma
Medium
Report
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma
3/20
05:30 am
hcm
Intended Retirement of Independent Non-executive Directors and changes of composition of board committees
Low
Report
Intended Retirement of Independent Non-executive Directors and changes of composition of board committees
3/20
04:38 am
hcm
HUTCHMED (China) Ltd (HCM) (Q4 2024) Earnings Call Highlights: Achieving Profitability and ... [Yahoo! Finance]
Low
Report
HUTCHMED (China) Ltd (HCM) (Q4 2024) Earnings Call Highlights: Achieving Profitability and ... [Yahoo! Finance]
3/19
08:07 pm
hcm
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 [Yahoo! Finance]
Low
Report
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 [Yahoo! Finance]
3/19
08:07 pm
hcm
HUTCHMED Reports 2024 Full Year Results and Provides Business Updates [Yahoo! Finance]
Low
Report
HUTCHMED Reports 2024 Full Year Results and Provides Business Updates [Yahoo! Finance]
3/19
08:00 pm
hcm
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025
Low
Report
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/7
06:05 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Apr 07
Medium
Report
Form 6-K HUTCHMED (China) Ltd For: Apr 07
3/31
06:03 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Mar 31
Low
Report
Form 6-K HUTCHMED (China) Ltd For: Mar 31
3/21
06:21 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Mar 21
Medium
Report
Form 6-K HUTCHMED (China) Ltd For: Mar 21
3/20
06:28 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Mar 20
Low
Report
Form 6-K HUTCHMED (China) Ltd For: Mar 20
3/19
08:16 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Mar 19
Medium
Report
Form 6-K HUTCHMED (China) Ltd For: Mar 19
3/19
08:10 am
hcm
Form 20-F HUTCHMED (China) Ltd For: Dec 31
Medium
Report
Form 20-F HUTCHMED (China) Ltd For: Dec 31
3/19
06:28 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Mar 19
Medium
Report
Form 6-K HUTCHMED (China) Ltd For: Mar 19
3/14
06:12 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Mar 14
Low
Report
Form 6-K HUTCHMED (China) Ltd For: Mar 14
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/13
HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating.
10.3%
10/11 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.0%
4/22 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.2%
9/30 CK Hutchison prices offering of Chi-Med share capital enabling deconsolidation and confirms its intention to hold Chi-Med as a strategic investment for the long term 4.9%
2/6 Chi-Med Announces the Exercise of Underwriters’ Over-allotment Option for Public Offering of ADSs 3.8%
7/30 Hutchison China MediTech Limited 2019 Q2 - Results - Earnings Call Slides [Seeking Alpha] 3.2%
4/17 Chi-Med Announces Surufatinib Granted U.S. FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors 3.1%
10/23 HUTCHISON CHINA/S (NASDAQ: HCM) is now covered by analysts at Bank of America Corp. They set a "buy" rating on the stock. 3.1%
1/13 Chi-Med Initiates a Phase II Trial of Surufatinib in Combination with Tuoyi in Patients with Advanced Solid Tumors 2.9%
3/3 Hutchison China MediTech Limited (HCM) Q4 2019 Earnings Call Transcript [The Motley Fool] 2.9%
10/11 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.0%
4/22 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.2%
9/30 CK Hutchison prices offering of Chi-Med share capital enabling deconsolidation and confirms its intention to hold Chi-Med as a strategic investment for the long term 4.9%
2/6 Chi-Med Announces the Exercise of Underwriters’ Over-allotment Option for Public Offering of ADSs 3.8%
7/30 Hutchison China MediTech Limited 2019 Q2 - Results - Earnings Call Slides [Seeking Alpha] 3.2%
4/17 Chi-Med Announces Surufatinib Granted U.S. FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors 3.1%
10/23 HUTCHISON CHINA/S (NASDAQ: HCM) is now covered by analysts at Bank of America Corp. They set a "buy" rating on the stock. 3.1%
1/13 Chi-Med Initiates a Phase II Trial of Surufatinib in Combination with Tuoyi in Patients with Advanced Solid Tumors 2.9%
3/3 Hutchison China MediTech Limited (HCM) Q4 2019 Earnings Call Transcript [The Motley Fool] 2.9%
TOP News Decliners
6/27
Chi-Med Announces Secondary Offering of American Depositary Shares
-18.8%
3/18 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -17.4%
1/21 Chi-Med Announces Proposed Public Offering of ADSs -12.6%
1/23 Chi-Med Announces Pricing of US$110 Million Public Offering of ADSs -9.8%
7/20 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -7.7%
9/3 Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma -5.3%
12/30 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -3.4%
2/25 Chi-Med to announce 2019 Final Results on Tuesday, March 3, 2020 – adjustment to announcement and presentation logistics due to travel restrictions -3.3%
9/27 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -2.9%
6/14 Chi-Med Announces that Surufatinib Phase III SANET-ep Study Has Met its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early -2.7%
3/18 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -17.4%
1/21 Chi-Med Announces Proposed Public Offering of ADSs -12.6%
1/23 Chi-Med Announces Pricing of US$110 Million Public Offering of ADSs -9.8%
7/20 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -7.7%
9/3 Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma -5.3%
12/30 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -3.4%
2/25 Chi-Med to announce 2019 Final Results on Tuesday, March 3, 2020 – adjustment to announcement and presentation logistics due to travel restrictions -3.3%
9/27 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -2.9%
6/14 Chi-Med Announces that Surufatinib Phase III SANET-ep Study Has Met its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early -2.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: